AI assistant
Sending…
Immunome Inc. — Director's Dealing 2023
Jun 12, 2023
32238_dirs_2023-06-12_41518981-8ffb-4752-992e-17348cccc9ac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2023-06-08
Reporting Person: Sarma Purnanand D (Director, President and CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-08 | Stock Option (Right to Buy) | $4.84 | A | 166500 | Acquired | 2033-06-08 | Common Stock (166500) | Direct |
Footnotes
F1: One-forty-eighth (1/48th) of the shares subject to such options shall vest monthly over forty-eight months after the grant date.
More from Immunome Inc.
Annual Report
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 3
Earnings Release
2026
Mar 3
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2025
Dec 31
Director's Dealing
2025
Dec 23
Major Shareholding Notification
2025
Dec 23